A number of other equities research analysts have also recently issued reports on MSTX. Zacks Investment Research cut shares of Mast Therapeutics from a buy rating to a hold rating in a report on Tuesday, July 12th. Maxim Group restated a buy rating and set a $5.00 price target on shares of Mast Therapeutics in a report on Tuesday, July 12th. Roth Capital restated a buy rating and set a $2.00 price target on shares of Mast Therapeutics in a report on Friday, July 15th. Canaccord Genuity restated a buy rating and set a $3.00 price target on shares of Mast Therapeutics in a report on Thursday, July 28th. Finally, Laidlaw cut shares of Mast Therapeutics from a buy rating to a neutral rating in a report on Wednesday, September 21st. Four analysts have rated the stock with a hold rating and two have issued a buy rating to the company. The stock currently has a consensus rating of Hold and a consensus price target of $2.07.
Mast Therapeutics (NASDAQ:MSTX) opened at 0.0848 on Friday. Mast Therapeutics has a 52 week low of $0.08 and a 52 week high of $0.71. The firm has a 50-day moving average price of $0.30 and a 200-day moving average price of $0.36. The firm’s market capitalization is $17.96 million.
Mast Therapeutics (NASDAQ:MSTX) last issued its quarterly earnings data on Tuesday, August 9th. The company reported ($0.05) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.06) by $0.01. Equities analysts forecast that Mast Therapeutics will post ($0.19) EPS for the current year.
An institutional investor recently raised its position in Mast Therapeutics stock. Vanguard Group Inc. increased its position in shares of Mast Therapeutics Inc (NASDAQ:MSTX) by 18.2% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 5,996,047 shares of the company’s stock after buying an additional 923,507 shares during the period. Vanguard Group Inc. owned approximately 3.11% of Mast Therapeutics worth $2,818,000 as of its most recent SEC filing.
Mast Therapeutics Company Profile
Mast Therapeutics, Inc is a biopharmaceutical company. The Company develops clinical-stage therapies for serious or life-threatening diseases with unmet needs. The Company focuses on developing new therapies for sickle cell disease, a chronic and genetic disorder classified as a rare, or orphan, disease in the United States of America and European Union, and for heart failure, a condition with an unmet need for treatment options.
Receive News & Ratings for Mast Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mast Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.